Genentech
Pharmaceutical Company
FACTBOX: Winners, losers in Senate health bill...board, sparing them from future potential payment cuts. BRAND BIOLOGIC DRUGMAKERS * Biological drugmakers such as Amgen Inc, Roche's Genentech unit maintained their 12-year period of exclusive sales for brand-name drugs before they... In this article: Medicare, Tax, Genentech, Medicare and Medicaid, America's Health Insurance Plans, Medicaid, Breast implant, Mentor, and Universal Health Services Inc |
-
BusinessWeek Online | 4 days ago
Can Roche Leave Genentech Alone?
...depositary receipts have climbed 12% this year, to 41. For nearly 20 years, Roche executives said that Genentech succeeded because it operated at arm's length, maintaining its own shareholders and management team and suffering little...
-
Reuters | 4 days ago
Roche CEO sees group outpacing market in 2009-paper
...in combination with a broader range of standard chemotherapies. [ID:nGEE5AO05D] Roche sealed a $47 billion buyout of U.S. partner Genentech earlier this year. Schwan said the group was now looking for small and mid-sized acquisitions.
In this article: Cancer, Avastin, Breast cancer, and U.S.
-
AP Online | November 18, 2009
Genentech, Biogen get FDA request on Rituxan
NEW YORK (AP) - Genentech Inc. and partner Biogen Idec Inc. said Wednesday the Food and Drug Administration is withholding a decision to expand approval of Rituxan as a leukemia treatment, pending further discussion. Neither company...
In this article: Food and Drug Administration, Biogen, Rituxan, Leukemia, Cancer, Rheumatoid arthritis, Cambridge, and NEW YORK
-
Centre Daily Times | November 18, 2009
Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia
SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass. - Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) issued...
In this article: Rituximab, Biogen Idec, FDA, CD20, NHL, Leukemia, Nausea, and Methotrexate
-
Genentech Submits Supplemental Applications to FDA for Avastin Combined with Commonly Used Chemotherapies for Women with Advanced Breast Cancer
...large intestine (2), heart attack (2) and diarrhea/abdominal pain/weakness/low blood pressure (2). About Genentech Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and...
In this article: Bevacizumab, Breast cancer, Paclitaxel, FDA, Surgery, Taxane, HER2, Capecitabine, and Cancer
-
Lawmakers used Genentech statements: report
...the e-mails it obtained show. The e-mails show the statements were based on information sent from Genentech employees to one of the company's lobbyists, Matthew Berzok, a lawyer at Ryan, MacKinnon, Vasapoli & Berzok, and the statements were...
In this article: Thomson Reuters, All rights reserved, Small business, Sonnenschein Nath & Rosenthal, NYSE, and Nasdaq
Trends
Loading...
More on Genentech
Description from Wikipedia:
Genentech Inc., a portmanteau of Genetic Engineering Technology, Inc., is a leading biotechnology corporation, which was founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer. It is considered to have founded the biotechnology industry. One of its founders, Boyer, is considered to be a pioneer in the field of recombinant DNA technology. In 1973, Boyer and his colleague Stanley Norman Cohen demonstrated that restriction enzymes could be used as "scissors" to cut DNA fragments of interest from one source, to be ligated into a similarly cut plasmid vector. While Cohen returned to the laboratory in academia, Robert Swanson contacted Boyer to found the company. Boyer worked with Arthur Riggs and Keiichi Itakura from the Beckman Research Institute, and the group became the first to successfully express a human gene in bacteria when they produced the hormone somatostatin in 1977. David Goeddel and Dennis Kleid were then added to the group, and contributed to its success with synthetic human insulin in 1978.
In March 2008, Genentech employed more than 11,000 people, and Arthur D. Levinson--who also served on the boards of Google and Apple --was the chairman and CEO. The Swiss pharmaceutical conglomerate Hoffmann-La Roche now completely owns Genentech after completing its purchase on 26th March, 2009 for about a total of 46.8 billion dollars.
- Name:
- Genentech, Inc.
- Location:
- South San Francisco, California, USA
- Founded:
- 1976
- Industry:
- Biotechnology
- Key People:
-
- Richard H. Scheller, Research
- Patrick Y. Yang, Technical Operations
- Denise Smith-Hams, HR, Genentech
- Hal Barron, Product Development
- Steve Grossman, HR North America
- Marc Tessier-Lavigne, Research
- Steve Krognes, CFO
- Chris Castro, Corporate Relations, North America
- Ian T. Clark, Commercial
- Rick Kentz, Legal
- Pascal Soriot, CEO
- Products:
- Activase/Cathflo, Nutropin, Pulmozyme, Rituxan, Herceptin, TNKase, Xolair, Avastin, Tarceva, Lucentis
- Revenue:
- $13.4 billion (non-GAAP) (2008)
- Net Income:
- $3.64 billion (non-GAAP) (2008)
- No. of Employees:
- c. 11,000 (December 31, 2008)
- Motto:
- "In business for life"
Explore everything named Genentech...
